{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=22", "query": { "intervention": "Combination Agent", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 5568, "total_pages": 557, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=23&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=21&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T12:37:43.490Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00027885", "title": "Phase II Bevacizumab + Tax In Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2001-11", "completion_date": "2010-08", "has_results": false, "last_update_posted_date": "2013-06-17", "last_synced_at": "2026-11-15T12:37:43.490Z", "location_count": 5, "location_summary": "Cleveland, Ohio • Middleburg Heights, Ohio • Orange, Ohio + 2 more", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Middleburg Heights", "state": "Ohio" }, { "city": "Orange", "state": "Ohio" }, { "city": "South Euclid", "state": "Ohio" }, { "city": "Westlake", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00027885" }, { "nct_id": "NCT02842125", "title": "Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Solid Tumor Cancer", "Recurrent Head and Neck Cancer" ], "interventions": [ { "name": "Ad-P53", "type": "DRUG" }, { "name": "Xeloda", "type": "DRUG" }, { "name": "Keytruda", "type": "DRUG" }, { "name": "Opdivo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MultiVir, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2018-11-20", "completion_date": "2020-05-08", "has_results": false, "last_update_posted_date": "2020-06-02", "last_synced_at": "2026-11-15T12:37:43.490Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02842125" }, { "nct_id": "NCT00493025", "title": "Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "gefitinib", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 19, "start_date": "2005-04", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2018-12-06", "last_synced_at": "2026-11-15T12:37:43.490Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00493025" }, { "nct_id": "NCT00768989", "title": "Phase IIB Pilot of Atazanavir + Raltegravir", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Atazanavir", "type": "DRUG" }, { "name": "Raltegravir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Tenofovir/Emtricitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 167, "start_date": "2008-11", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2012-02-24", "last_synced_at": "2026-11-15T12:37:43.490Z", "location_count": 9, "location_summary": "Phoenix, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00768989" }, { "nct_id": "NCT02872597", "title": "Phase I, Placebo-Controlled, Blinded Pilot Study of Ipratropium in Children Admitted to the ICU With Status Asthmaticus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Status Asthmaticus" ], "interventions": [ { "name": "Ipratropium", "type": "DRUG" }, { "name": "0.9% Sodium Chloride", "type": "DRUG" }, { "name": "Albuterol", "type": "DRUG" }, { "name": "corticosteroids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University Hospitals Cleveland Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 30, "start_date": "2016-09-05", "completion_date": "2018-08-16", "has_results": false, "last_update_posted_date": "2019-04-18", "last_synced_at": "2026-11-15T12:37:43.490Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02872597" }, { "nct_id": "NCT06952010", "title": "A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Advanced Solid Tumor", "Metastatic Solid Tumor", "Immune Sensitive Tumor" ], "interventions": [ { "name": "XB628", "type": "BIOLOGICAL" }, { "name": "Zanzalintinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 303, "start_date": "2025-05-01", "completion_date": "2027-11-30", "has_results": false, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-11-15T12:37:43.490Z", "location_count": 11, "location_summary": "San Francisco, California • New Haven, Connecticut • Tampa, Florida + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06952010" }, { "nct_id": "NCT00002238", "title": "Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Interferon beta-1b", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-11-15T12:37:43.490Z", "location_count": 25, "location_summary": "Berkeley, California • Los Angeles, California • Oakland, California + 13 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002238" }, { "nct_id": "NCT01333943", "title": "Saphenous Nerve Block Versus Femoral Nerve Block for Total Knee Arthroplasty", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Total Knee Arthroplasty" ], "interventions": [ { "name": "Study Group: Experimental", "type": "PROCEDURE" }, { "name": "Control Group", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Hospital for Special Surgery, New York", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 94, "start_date": "2011-03", "completion_date": "2011-11", "has_results": true, "last_update_posted_date": "2022-05-11", "last_synced_at": "2026-11-15T12:37:43.490Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01333943" }, { "nct_id": "NCT04729608", "title": "Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Platinum-resistant Ovarian Cancer" ], "interventions": [ { "name": "Batiraxcept", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Aravive, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 366, "start_date": "2021-04-22", "completion_date": "2023-08-04", "has_results": false, "last_update_posted_date": "2023-10-30", "last_synced_at": "2026-11-15T12:37:43.490Z", "location_count": 84, "location_summary": "Mobile, Alabama • Burbank, California • Los Angeles, California + 74 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Burbank", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04729608" }, { "nct_id": "NCT00003117", "title": "Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 584, "start_date": "1997-10", "completion_date": "2006-01", "has_results": false, "last_update_posted_date": "2016-06-30", "last_synced_at": "2026-11-15T12:37:43.490Z", "location_count": 35, "location_summary": "La Jolla, California • San Francisco, California • Wilmington, Delaware + 24 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Wilmington", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003117" } ] }